Background: We evaluated the efficacy and tolerability of tamsulosin versus terazosin in patients with signs and symptoms of benign prostatic hyperplasia (BPH). Methods: Patients (N = 1,993) were randomized to tamsulosin (0.4 mg/day) or terazosin (5 mg/day, following titration). The primary efficacy endpoint was total American Urological Association Symptom Index (AUA-SI) score after 4 days of ...

An efficient dispersive liquid-liquid microextraction using tetraalkylammonium bromide coated silver nanoparticles (DLLME-AgNPs) prepared in chloroform has been successfully applied as electrostatic affinity probes to the microextraction and preconcentration of terazosin prior to spectrofluorimetry analysis. This technique is based on a ternary system of solvents, where appropriate amount of mi...

PURPOSE We determined the efficacy and safety of a relatively high dose of terazosin (5mg) in Korean patients with lower urinary tract symptoms (LUTS), with or without concomitant hypertension. MATERIALS AND METHODS From July to December 2006, 200 men who consecutively presented with LUTS were prospectively studied. Eight weeks after treatment, blood pressure (BP), uroflowmetry, and Internati...

Thermal analysis of some antihypertensive drugs, Telmisartan, Cilazapril and Terazosin HCL was achieved. Thermogravimetry, derivative thermogravimetry and differential thermal analysis were used through the work. Thermogravimetric parameters such as activation energy, frequency factor and reaction order were calculated. The results show the stability value decrease in the order Telmisartan > Ci...

Benign prostatic hyperplasia (BPH), common in aging males is often treated with alpha1-adrenoceptor (AR) antagonists. In view of known hypotensive effect of most of the alpha1-AR antagonists, this work examined the effect of a selected alpha1-AR antagonist, terazosin on the baroreceptor mediated regulation of blood pressure. The three doses of terazosin (10, 100, 300 microg/kg body weight) used...

OBJECTIVES To evaluate the cost-effectiveness and functional status effects of terazosin, an alpha(1)-adrenoceptor antagonist, compared with placebo in the treatment of men with moderate to severe, symptomatic, benign prostatic hyperplasia (BPH). METHODS Prospective, randomized, double-blind, placebo-controlled multicenter trial of 2084 patients was conducted at 15 academic regional centers a...

OBJECTIVE To assess whether the alpha1-adrenoceptor antagonists currently available for the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) (alfuzosin, terazosin, doxazosin and tamsulosin) can be distinguished with regard to clinical efficacy and/or tolerability. METHODS Up-to-date analysis of clinical placebo-controlled or direct comparative ...

Two independent signal transduction pathways regulate lymphocyte amiloride-sensitive sodium channels (ASSCs), one utilizing cAMP as a second messenger and the other utilizing a GTP-binding protein. This implies that two plasma membrane receptors play a role in the regulation of lymphocyte ASSCs. In this study, we tested the hypothesis that α1- and α2-adrenergic receptors independently regulate ...

The aim of this study was to determine whether pre-treatment of human skin with the alpha(1)-adrenoceptor antagonist terazosin would block vasoconstrictor responses and axon-reflex vasodilatation to the alpha(1)-adrenoceptor agonist methoxamine. Drugs were administered by iontophoresis into the skin of the forearm of 15 healthy participants, and skin blood flow was monitored with a laser Dopple...